Sarah Rusch

670 total citations
20 papers, 525 citations indexed

About

Sarah Rusch is a scholar working on Epidemiology, Infectious Diseases and Surgery. According to data from OpenAlex, Sarah Rusch has authored 20 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 5 papers in Infectious Diseases and 5 papers in Surgery. Recurrent topics in Sarah Rusch's work include Respiratory viral infections research (11 papers), Pneumonia and Respiratory Infections (5 papers) and Viral gastroenteritis research and epidemiology (4 papers). Sarah Rusch is often cited by papers focused on Respiratory viral infections research (11 papers), Pneumonia and Respiratory Infections (5 papers) and Viral gastroenteritis research and epidemiology (4 papers). Sarah Rusch collaborates with scholars based in Belgium, United States and Argentina. Sarah Rusch's co-authors include Damayanthi Devineni, David Polidori, Christopher R. Curtin, María J. Gutiérrez, Joseph Murphy, Paul Rothenberg, Nicole Vaccaro, Ewa Wajs, Marita Stevens and Dymphy Huntjens and has published in prestigious journals such as Clinical Infectious Diseases, Pain and The Journal of Infectious Diseases.

In The Last Decade

Sarah Rusch

20 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Rusch Belgium	12	270	200	142	116	75	20	525
Mary Seger United States	13	295 1.1×	161 0.8×	79 0.6×	79 0.7×	53 0.7×	21	571
Vikas S. Sridhar Canada	13	274 1.0×	160 0.8×	40 0.3×	97 0.8×	59 0.8×	55	483
Celal Ulaşoğlu Türkiye	13	149 0.6×	111 0.6×	304 2.1×	73 0.6×	30 0.4×	34	519
Anna R. Dover United Kingdom	13	423 1.6×	220 1.1×	48 0.3×	42 0.4×	12 0.2×	29	606
Pedro von Hafe Portugal	8	56 0.2×	70 0.3×	77 0.5×	53 0.5×	44 0.6×	26	328
Peng Men China	12	111 0.4×	57 0.3×	54 0.4×	70 0.6×	14 0.2×	29	371
Aziz Yazar Türkiye	10	37 0.1×	112 0.6×	87 0.6×	97 0.8×	103 1.4×	22	508
Rob Spanjersberg Netherlands	9	110 0.4×	46 0.2×	56 0.4×	93 0.8×	50 0.7×	10	382
Daniela Patrono Italy	11	120 0.4×	125 0.6×	220 1.5×	89 0.8×	39 0.5×	30	536
G Rizzo Italy	12	93 0.3×	228 1.1×	22 0.2×	59 0.5×	55 0.7×	38	527

Countries citing papers authored by Sarah Rusch

Since Specialization

Citations

This map shows the geographic impact of Sarah Rusch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Rusch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Rusch more than expected).

Fields of papers citing papers by Sarah Rusch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Rusch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Rusch. The network helps show where Sarah Rusch may publish in the future.

Co-authorship network of co-authors of Sarah Rusch

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Rusch. A scholar is included among the top collaborators of Sarah Rusch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Rusch. Sarah Rusch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferrero, Fernando, Chien‐Yu Lin, Johannes G. Liese, et al.. (2024). CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Pediatric Drugs. 26(4). 411–427. 6 indexed citations

Nilsson, Anna, John Pullman, Piotr Napora, et al.. (2023). A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection. Clinical Microbiology and Infection. 29(10). 1320–1327. 9 indexed citations

Loge, Christine de la, et al.. (2021). Monitoring Severity of Respiratory Syncytial Virus (RSV) in Infants and Young Children Using the Pediatric RSV Electronic Severity and Outcome Rating System (PRESORS): Results of Initial Quantitative Validation. Patient Related Outcome Measures. Volume 12. 247–265. 3 indexed citations

Martinón‐Torres, Federico, Sarah Rusch, Dymphy Huntjens, et al.. (2020). Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study. Clinical Infectious Diseases. 71(10). e594–e603. 20 indexed citations

Remmerie, Bart, Thomas Van Looy, Sarah Rusch, et al.. (2019). Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor. Advances in Therapy. 37(1). 578–591. 2 indexed citations

Malcolm, Bruce A., et al.. (2018). PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials. Antiviral Research. 153. 70–77. 5 indexed citations

Stevens, Marita, Sarah Rusch, John P. DeVincenzo, et al.. (2018). Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. The Journal of Infectious Diseases. 218(5). 748–756. 55 indexed citations

Martinón‐Torres, Federico, Sarah Rusch, Dymphy Huntjens, et al.. (2018). 1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005. Open Forum Infectious Diseases. 5(suppl_1). S566–S567. 4 indexed citations

Huntjens, Dymphy, et al.. (2017). Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects. Clinical Pharmacokinetics. 56(11). 1331–1342. 11 indexed citations

10.

Levin, Yotam, et al.. (2016). A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine. 34(44). 5262–5272. 38 indexed citations

11.

Israel, Samuel, Sarah Rusch, John P. DeVincenzo, et al.. (2016). Effect of Oral JNJ-53718678 (JNJ-678) on Disease Severity in Healthy Adult Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus (RSV): A Placebo-Controlled Challenge Study. Open Forum Infectious Diseases. 3(suppl_1). 13 indexed citations

12.

Devineni, Damayanthi, Christopher R. Curtin, Thomas Marbury, et al.. (2015). Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. Clinical Therapeutics. 37(3). 610–628.e4. 39 indexed citations

13.

Devineni, Damayanthi, Nicole Vaccaro, David Polidori, Sarah Rusch, & Ewa Wajs. (2014). Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants. Clinical Therapeutics. 36(5). 698–710. 42 indexed citations

14.

Stein, Peter, Jolene Kay Berg, Linda Morrow, et al.. (2014). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism. 63(10). 1296–1303. 43 indexed citations

15.

Devineni, Damayanthi, Christopher R. Curtin, David Polidori, et al.. (2013). Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. 53(6). 601–610. 168 indexed citations

16.

Hoeben, Eef, Johan W. Smit, David Upmalis, et al.. (2012). Dose-response relationship after single oral dose administrations of morphine and oxycodone using laser-evoked potentials on UVB- and capsaicin-irritated skin in healthy male subjects. Pain. 153(8). 1648–1656. 14 indexed citations

17.

Zannikos, Peter, Dennis R. Doose, G Leitz, et al.. (2011). Pharmacokinetics and Tolerability of Rabeprazole in Children 1 to 11 Years Old With Gastroesophageal Reflux Disease. Journal of Pediatric Gastroenterology and Nutrition. 52(6). 691–701. 16 indexed citations

18.

Quiroz, Jorge A., et al.. (2011). Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.. PubMed. 8(6). 20–8. 12 indexed citations

19.

Rusch, Sarah, et al.. (2010). Risperidone Long‐Acting Injection: Pharmacokinetics Following Administration in Deltoid Versus Gluteal Muscle in Schizophrenic Patients. The Journal of Clinical Pharmacology. 50(9). 1011–1021. 23 indexed citations

20.

Jacobs, Tom, Filip De Ridder, Sarah Rusch, et al.. (2008). Including Information on the Therapeutic Window in Bioequivalence Acceptance. Pharmaceutical Research. 25(11). 2628–2638. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact